

PROVIDER Update



CONTRACTUAL | APRIL 4, 2023 | UPDATE 23-279 | 5 PAGES

Medication Trend Updates and Formulary Changes – 2nd Quarter 2023

Review formulary changes and medication safety issues

Stay up to date with information about:

- Availability of Humira® biosimilars in 2023.
- Removal of X-Waiver for medications used for opioid use disorder (OUD).
- Changes to the Health Net* commercial Formulary, Medi-Cal Preferred Drug List (PDL) and Medicare Part D Formulary for the first quarter of 2023.

Humira biosimilars enter the market in 2023

Several FDA-approved biosimilars of Humira will hit the U.S. market this year. Biosimilars have slightly different structures than the referenced product but demonstrate the same effect in treating a disease. In addition, biosimilars are lower-cost medications than their brand biologics.

Humira is FDA-approved to treat several autoimmune conditions in adult and children including rheumatoid arthritis, Crohn's disease and ulcerative colitis. The Humira biosimilars launching in 2023 are approved for most of the same indications as Humira, with two exceptions. The biosimilars are not approved to treat hidradenitis suppurativa or uveitis. They also vary in their available concentrations and doses as well. One or more of the biosimilars will have the interchangeability designation. An interchangeable biosimilar can be automatically substituted for Humira at a pharmacy without first consulting with the prescribing physician. This will eliminate the need for another prescription.

Most Humira biosimilars are expected to launch in July 2023, but Amjevita was launched on January 31, 2023.

THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer/Group
 - HMO/POS/HSP
 - EPO
 - PPO
- Wellcare By Health Net
 - Medicare Advantage (HMO)
 - Medicare Advantage (PPO)
- Medi-Cal
 - Kern
 - Los Angeles
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Ambetter HMO – 888-926-2164

Health Net Employer Group HMO, POS, HSP, PPO, & EPO – 800-641-7761

Medicare (individual & employer group) (Wellcare By Health Net) – 800-929-9224

Medi-Cal (including CS and ECM providers) – 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

Humira Biosimilar Brand Products	Anticipated Launch Date	Interchangeability Designation
Amjevita	Launched on January 31, 2023	No
Abrilada	July 2023	Under review
Cyltezo	July 2023	Yes
Hadlima	July 2023	No; expected post-launch
Hulio	July 2023	No
Hyrimoz	July 2023	No
Idacio	July 2023	No
Yusimry	July 2023	No

X-Waiver requirement is removed for all prescriptions used for OUD

On January 12, 2023, the Drug Enforcement Administration (DEA) confirmed in a letter to registrants that Section 1262 of the Consolidated Appropriations Act, 2023 eliminated the DATA-Waiver Program. Effective immediately, waiver applications will no longer be accepted.

All buprenorphine prescriptions now only require a standard DEA registration number. The previously used DATA-Waiver (also known as X-Waiver) registration numbers are no longer needed for any prescription. Any practitioner with a current DEA registration that includes Schedule III authority may now prescribe buprenorphine for OUD in their practice. Prescribers no longer have a limit on the number of patients they can treat for OUD with buprenorphine.

For additional information on the removal of the DATA-Waiver requirement, see the statement issued by the Substance Abuse and Mental Health Services Administration (SAMHSA) website.

Reference: <https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement>

Changes to the Commercial Formulary, Medi-Cal PDL and Medicare Part D Formulary

The Health Net Pharmacy and Therapeutics (P&T) Committee includes practicing physicians, pharmacists and other health care professionals. Each quarter, the P&T Committee reviews medications on the Formulary for commercial members, the PDL for Medi-Cal members, and the Medicare Part D Formulary for Medicare members to determine which medications remain on the same tier and which are moved. A table listing some recent changes begins on page 4. The list contains brand-name prescription medications, status, other medication choices, and comments for the second quarter of 2023.

The complete lists of the commercial Formularies, Medi-Cal PDLs and Medicare Part D Formularies are available on the Health Net provider website as listed below under Additional Information.

Pharmacy help line

For more information regarding changes to the Health Net Commercial Formulary or Health Net Medi-Cal Preferred Drug List, or Medicare Part D Formulary, contact the proper pharmacy phone numbers listed below:

Product	Phone number	Fax number
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-675-6110	833-953-3436
Commercial Pharmacy Services	800-548-5524, option #3	866-399-0929
Medicare Pharmacy Service Center	800-867-6564	800-977-8226

Additional information

Providers are encouraged to access Health Net’s provider portal online at provider.healthnetcalifornia.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center at:

Line of business	Phone number	Email address
IFP Ambetter PPO	844-463-8188	provider_services@healthnet.com
IFP Ambetter HMO	888-926-2164	
Health Net Employer Group HMO, POS, HSP, PPO, & EPO	800-641-7761	
Medicare (Individual & Employer Group)	800-929-9224	
Medi-Cal	800-675-6110	N/A

Health Net Commercial Formulary, Medi-Cal PDL and Medicare Part D Formulary Changes

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	

Injectable preparations

Hemgenix® (etranacogene dezaparvovec-drlb)	Medical Benefit ²	Medical Benefit ²	Medical Benefit ²				<p>An adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:</p> <ul style="list-style-type: none"> • Currently use Factor IX prophylaxis therapy, or • Have current or historical life-threatening hemorrhage, or • Have repeated, serious spontaneous bleeding episodes.
--	------------------------------	------------------------------	------------------------------	--	--	--	--

Skysona® (elivaldogene autotemcel)	Medical Benefit ²	Medical Benefit ²	Medical Benefit ²				To slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Early, active CALD refers to asymptomatic or mildly symptomatic (neurologic function score, NFS ≤ 1) boys who have gadolinium enhancement on brain magnetic resonance imaging (MRI) and Loes scores of 0.5-9.
Tzield™ (teplizumab-mzwv)	Medical Benefit ²	Medical Benefit ²	Medical Benefit ²				A CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
Amjevita™ (adalimumab-atto)	Tier 4 ² (Tier 4 ²)	Tier 5 ²	Carved out				Biosimilar to the brand Humira®. For commercial, Amjevita is co-preferred with Humira.

¹Medicare Part D: Health Net Gold Select (HMO), Health Net Healthy Heart (HMO), Health Net Jade (HMO C-SNP), Health Net Ruby (HMO), Health Net Ruby Select (HMO), Health Net Sapphire (HMO), Health Net Violet 1 (PPO), Health Net Violet 2 (PPO), Health Net Violet 3 (PPO), Health Net Violet 4 (PPO)

²Prior authorization (PA) is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.

NF indicates nonformulary; NP indicates nonpreferred. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.